A number of other analysts have also recently weighed in on ONCE. Zacks Investment Research cut shares of Spark Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 14th. Mizuho restated a “hold” rating and issued a $114.50 target price on shares of Spark Therapeutics in a report on Monday, August 12th. Thirteen investment analysts have rated the stock with a hold rating, The company presently has a consensus rating of “Hold” and an average price target of $106.00.
ONCE stock traded down $0.14 during trading on Tuesday, hitting $109.85. 768 shares of the company’s stock were exchanged, compared to its average volume of 900,132. The business has a 50-day moving average price of $108.63 and a two-hundred day moving average price of $103.28. The company has a current ratio of 4.67, a quick ratio of 4.35 and a debt-to-equity ratio of 0.35. The stock has a market capitalization of $4.24 billion, a price-to-earnings ratio of -52.10 and a beta of 2.05. Spark Therapeutics has a 52-week low of $34.53 and a 52-week high of $114.20.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC increased its holdings in shares of Spark Therapeutics by 4,568.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 887 shares of the biotechnology company’s stock valued at $86,000 after acquiring an additional 868 shares during the period. CSat Investment Advisory L.P. bought a new stake in shares of Spark Therapeutics in the 2nd quarter worth $113,000. Nisa Investment Advisors LLC increased its holdings in shares of Spark Therapeutics by 651.6% in the 3rd quarter. Nisa Investment Advisors LLC now owns 1,165 shares of the biotechnology company’s stock worth $113,000 after purchasing an additional 1,010 shares in the last quarter. Janney Montgomery Scott LLC purchased a new position in shares of Spark Therapeutics in the second quarter worth $202,000. Finally, Ancora Advisors LLC purchased a new position in shares of Spark Therapeutics in the second quarter worth $205,000. Institutional investors and hedge funds own 88.36% of the company’s stock.
About Spark Therapeutics
Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec) for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy and viable retinal cells.
Further Reading: Basic Economics creates winners and losers
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.